Carbohydrate Research 350 (2012) 14–19

Contents lists available at SciVerse ScienceDirect

Carbohydrate Research

journal homepage: www.elsevier.com/locate/carres

Synthesis of 1,2,3-triazole glycoconjugates as inhibitors of α-glucosidases

David R. da Rocha [a], Wilson C. Santos [b,d], Emerson S. Lima [c], Vitor F. Ferreira [a,*]

[a] Universidade Federal Fluminense, Instituto de Química, Departamento de Química Orgânica, CEG, Campus do Valonguinho, 24210-141 Niterói, RJ, Brazil
[b] Universidade Federal Fluminense, Faculdade de Farmácia, Programa de Pós-Graduação em Ciências Aplicadas a Produtos Para Saúde (PPG-CAPS), Rua Mário Viana, 523, 24241-000 Niterói, Brazil
[c] Universidade Federal do Amazonas, Faculdade de Ciências da Saúde, 69010-300 Manaus, AM, Brazil
[d] Instituto Teófilo Hernando, Departamento de Farmacología, Facultad de Medicina, Universidad Autónoma de Madrid, Avda Arzobispo Morcillo, 4, 28029, Spain

ARTICLE INFO

Article history:
Received 3 November 2011
Received in revised form 22 December 2011
Accepted 25 December 2011
Available online 3 January 2012

Keywords:
Triazole
Glycoconjugates
α-Glucosidase

ABSTRACT

Ten new 1,2,3-triazole glycoconjugates were synthesized from D-glucose and evaluated in in vitro assays for their ability to inhibit the enzyme α-glucosidase. Most of the compounds had low activity or were inactive when compared with acarbose. However, the derivative 1,2-*O*-isopropylidene-3-phenyl-5-(4-phenyl-1*H*-1,2,3-triazole-1-yl)-α-D-ribofuranose (**19i**) possessed activity comparable with the standard drug. The influence of the phenyl group on carbon 3 of the carbohydrate framework is discussed.

1. Introduction

A glycosidic bond is a covalent chemical bond between the anomeric carbon atom of a saccharide and some other group or molecule. Many polysaccharides are formed from the union of monosaccharides by α- or β-glycosidic bonds. During the digestion process, these bonds are hydrolyzed by specific glycosidase enzymes that liberate the carbohydrate units as nutrients.[1] For instance, α-amylase enzymes are produced in the digestive system to break down the α-glycosidic bonds of starch. Several glycosidase enzymes are involved in important biological processes,[2] such as intestinal digestion and the lysosomal catabolism of glycoconjugates. Additionally, these enzymes are involved in virus production[3,4] and cancer metastasis[5–7] and are targets for anti-hyperglycemic pharmacological agents. In this regard, digestive α-glucosidases control rapid increases in blood glucose and therefore are therapeutically useful for the treatment of metabolic diseases such as diabetes mellitus.[8]

Many organisms have endogenous inhibitors that control the activity of glycosidases and glycosyl transferases. For instance, nojirimycin (**1**) and deoxynojirimycin (**2**) are potent inhibitors for α- and β-glucosidases and are produced by several natural sources. Since the discovery of these compounds, several other glycosidase inhibitors have been isolated from plants and microorganisms.[9] The search for α-glucosidase inhibitors led to the isolation of acarbose (**3**), marketed as Glucobay® and Precose, from the Actinoplanes strain SE 50 and is used as a potent sucrase inhibitor (Fig. 1).[10] Acarbose consists of a polyhydroxylated aminocyclohexene derivative (valienamine) that is linked via its nitrogen atom to 6-deoxyglucose, which is α-(1→4)-linked to a maltose moiety (Fig. 1). This compound inhibits pig intestinal sucrase with an IC_{50} of 0.5 mM.[11] After many clinical investigations, acarbose was introduced in the market in 1990 for the treatment of type 2 diabetes mellitus.[7] The inhibition of pancreatic α-amylase and intestinal α-glucosidases has demonstrated great value in the control of blood glucose levels by slowing down the starch digestion rate.[12–16] The strong inhibition of human amylases by acarbose (IC_{50} 108.8 ± 12.3 μM) is attributed both to the partial planarity of the valienamine ring and to the presence of strong electrostatic interactions between the carboxyl groups at the active site and the protonated nitrogen atom of the inhibitor.

Polysubstituted five-membered azaheterocycles have been described as potent glycosidase inhibitors. These heterocycles mimic the sugars moieties, and notable structural scaffolds include pyrrole-, imidazole-,[17,18] [1,2,3]-triazole-[19–24], and tetrazolo-glycoderivatives.[25,26]

The importance of triazolic compounds is of particular interest for medicinal chemistry, and many of them have been employed as pharmaceutically active compounds or as prototypes for potential drugs. In this regard, [1,2,3]-triazoles have gained increasing attention due to the ease of their incorporation into molecules via 'click' chemistry.[27,28] These heterocycles can actively participate in hydrogen bonding and dipole–dipole interactions due to their strong dipole moments. Additionally, they are extremely stable against hydrolysis and oxidative/reductive conditions. They are

* Corresponding author.
E-mail address: cegvito@vm.uff.br (V.F. Ferreira).

0008-6215/$ - see front matter © 2012 Elsevier Ltd. All rights reserved.
doi:10.1016/j.carres.2011.12.026



Figure 1. Some examples of α-glucosidases inhibitors.

significantly active against various biological targets[29] such as tuberculostatic,[12,30] antiplatelet agents,[31] dopamine D_2 receptors related to schizophrenia,[32] and anticonvulsant,[33] anti-inflammatory,[34,35] anti-allergic,[36–39] antiviral,[40–43] and antimicrobial agents.[19,44–47] Several 1,2,3-triazoles are described in the literature as glycoconjugates for the inhibition of α-glucosidases (**4–7**, Fig. 1).[19–24]

Compounds with triazole as the core system have promising α-glucosidase inhibition activity. Our research group recently reported the synthesis of 1,2,3-glycotriazole derivatives, and two of them displayed a high degree of inhibition of the α-glucosidase enzyme.[48] Notably, β-D-ribosyl triazoles **8** and **9** showed the greatest activity (Fig. 2). In a continuing effort to find new glycotriazole analogues and to better understand the relationship between structural changes and the activities of these substances, we investigated structural changes in these compounds by introducing a phenyl group at the C-3 carbon of the carbohydrate and moving the isopropylidene moiety to the C-1 and the C-2 positions as indicated in Figure 2.

2. Results

Melting points were observed on a Fischer–Jones apparatus and are uncorrected. Analytical grade solvents were used.[49] Dioxane was distilled before use. Reagents were purchased from Aldrich or Acros Chemical Co. Column chromatography was performed on silica gels (Acros Organics 0.035–0.070 mm, pore diameter 6 nm). Yields refer to the chromatographically and spectroscopically homogeneous materials. Reactions were monitored by thin layer chromatography (TLC) and were carried out on 0.25 mm E. Merck silica gel plates (60F-254) using UV light as the visualizing agent and an ethanolic solution of sulfuric acid. Infrared spectra were recorded on a Perkin–Elmer FT-IR Spectrum One spectrophotometer was calibrated relative to the 1601.8 cm^{-1} absorbance of polystyrene. Optical rotation measurements were obtained using an Acatec PDA 9300 polarimeter. NMR spectra were recorded on a Varian Unity Plus VXR (300 MHz) instrument in DMSO-d_6 and $CDCl_3$ solutions, and tetramethylsilane was used as the internal standard ($\delta = 0$ ppm). Elemental analysis was used to determine the purity of the compounds for which biological data were determined.

To obtain the triazoles planned in this work, we followed the synthetic route from D-glucose (**10**) as described in Scheme 1. The route consisted of a series of simple reactions involving the initial formation of a diacetonide (**11**),[50] followed by the oxidation of the hydroxyl group at the C-3 position and the addition of the phenyl group to the carbonyl, which occurs selectively at the *si* face,[51] producing **12**. The selective removal of the isopropylidene group



Figure 2. Planning concepts for the synthesis of glycotriazoles **19a–j**.



Scheme 1. Synthetic route used for the preparation of 1,2,3-glycotriazoles **19a–j**.

from the hydroxyl groups attached to C-5 and C-6, followed by the oxidative cleavage of the diol and the reduction of the aldehyde, led to the formation of **16**. Then, the introduction of a tosyl group at the C-5 position followed by the nucleophilic displacement by an azide group led to the key intermediate **18**. Finally, the 1,3-dipolar cycloaddition reaction was carried out with a series of terminal alkynes to generate the desired 1,2,3-triazoles **19a–j** linked to D-ribose unit at carbon. All of the 1,2,3-glycotriazoles were obtained with improved yields, were fully characterized by ^{1}H NMR, ^{13}C NMR, IR (infrared) spectroscopy, and elemental analysis and are depicted at Figure 3. Preparation of intermediate **15** from **11** and all data related to compounds **12**–**15** can be found in a previous work of our research group.[52]

2.1. 1,2-*O*-Isopropylidene-3-*C*-phenyl-α-D-ribofuranose (16)

A round-bottomed flask equipped with a magnetic stirring bar was loaded with **15** (2.5 g, 9.7 mmol, 1 equiv) and was dissolved in 80% EtOH (50 mL). Next, $NaBH_4$ (720 mg, 2 equiv) was dissolved in 80% EtOH (30 mL) and added to the reaction mixture. The reaction proceeded for 12 h and then was neutralized with a saturated solution of NH_4Cl, and the EtOH was removed under reduced pressure. The resulting mixture was extracted with CH_2Cl_2, and the organic layer was washed with water, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to yield **16** (85%, 2.1 g, 7.9 mmol) as a white solid (mp: 112–114 °C). IR ν_{max} (cm^{-1}; film): 1377 ([$C(CH_3)_2$]), 3506 (OH). ^{1}H NMR (300 MHz, $CDCl_3$) δ (J in Hz): 7.38–7.31 (5H, m, phenyl), 6.13 (1H, d, J = 3.9, H-1), 4.44 (1H, d, J = 4.1, H-2), 4.18 (1H, dd, J = 7.8, 3.4, H-4), 3.46 (1H, dd, J = 12.0, 3.4, H-5a or H-5b), 3.22 (1H, dd, J = 12.0, 7.8, H-5a or H-5b), 1.67 (3H, s, CH_3), 1.41 (1H, s, CH_3). ^{13}C NMR (75 MHz, $CDCl_3$) δ: 138.4 (C-1–phenyl), 128.3, 127.8, 124.9 (C-2–C-6-phenyl), 112.9 [$C(CH_3)_2$], 104.9 (C-1), 84.6 (C-4), 84.4 (C-2), 79.8 (C-3), 61.6 (C-5), 26.6, 26.5 (CH_3). $[\alpha]_D^{20}$ +51 (c 1.2, CH_2Cl_2). Anal. Calcd for $C_{14}H_{18}O_5$: C, 63.15; H, 6.81. Found: C, 63.98; H, 7.16.



Figure 3. Structures and yields of the 1,2,3-glycotriazoles **19a–j**.

2.2. 1,2-*O*-Isopropylidene-3-*C*-phenyl-5-*O*-tosyl-α-D-ribofuranose (17)

A round-bottomed flask equipped with a magnetic stirring bar was loaded with **16** (2.0 g, 7.7 mmol, 1 equiv) and was dissolved in dry pyridine (6.0 mL). The mixture was placed in an ice bath before the addition of tosyl chloride (1.8 g, 1.2 equiv) and 1 crystal of DMAP. The reaction proceeded for 30 min in an ice bath and then for 3 h at room temperature. Then, 1.0 mL of water was added to the reaction. The resulting mixture was dissolved in EtOAc (20 mL) and washed with a 10% $CuSO_4$ aqueous solution and with water. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to yield **17** (90%, 2.8 g, 6.7 mmol) as a white solid (mp: 122–124 °C).[53] IR ν_{max} (cm^{-1}; film): 1358 ([$C(CH_3)_2$]), 3480 (OH). ^{1}H NMR (300 MHz, $CDCl_3$) δ (J in Hz): 7.28–7.71 (9H, m, phenyl and tosyl), 6.07 (1H, d, J = 4.0, H-1), 4.37 (1H, d, J = 4.0, H-2), 4.18 (1H, dd, J = 8.3, 2.5, H-4), 3.93 (1H, dd, J = 11.3, 2.5, H-5a or H-5b), 3.55 (1H, dd, J = 11.0, 8.3, H-5a or H-5b), 2.43 (3H, s, CH_3-tosyl), 1.61 (3H, s, CH_3), 1.38 (3H, s, CH_3). ^{13}C NMR (75 MHz, $CDCl_3$) δ: 144.7 (C-1-tosyl), 132.8

(C-1-phenyl), 129.7, 128.5, 128.1, 127.9, 124.8 (C-2–C-6-phenyl and tosyl), 113.5 [$C(CH_3)_2$], 105.0 (C-1), 84.1 (C-2), 81.6 (C-4), 79.8 (C-3), 68.7 (C-5), 26.5, 26.4 (CH_3), 21.6 (CH_3-tosyl). $[\alpha]_D^{20}$ +22 (*c* 1.1, CH_2Cl_2). Anal. Calcd for $C_{21}H_{24}O_7S$: C, 59.99; H, 5.75. Found: C, 60.30; H, 5.80.

2.3. 1,2-*O*-Isopropylidene-3-*C*-phenyl-5-azido-α-D-ribofuranose (18)

A round-bottomed flask equipped with a magnetic stirring bar was loaded with **17** (2.5 g, 6.1 mmol), sodium azide (2.3 g), and dry DMF (21 mL). The mixture was heated to 120 °C and the reaction proceeded for 12 h. The organic solvent was concentrated under reduced pressure, and the crude product was dissolved in EtOAc (20 mL) and washed with water. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to yield **18** (75%, 1.3 g, 4.5 mmol) as a yellow oil.[54] IR ν_{max}(cm^{-1}; film): 1377 ([$C(CH_3)_2$]), 2101 (N_3), 3522 (OH). ^{1}H NMR (300 MHz, $CDCl_3$) δ (*J* in Hz): 7.30–7.42 (5H, m, phenyl), 6.14 (1H, d, *J* = 3.9, H-1), 4.45 (1H, d, *J* = 3.9, H-2), 3.49 (1H, dd, *J* = 13.4, 3.2, H-5a or H-5b), 3.29 (1H, s, H-4), 2.85 (1H, dd, *J* = 13.2, 8.8, H-5a or H-5b), 1.68 (3H, s, CH_3), 1.42 (3H, s, CH_3). ^{13}C NMR (75 MHz, $CDCl_3$) δ: 138.0 (C-phenyl), 128.5, 128.0, 124.9 (C-2–C6-phenyl), 113.0 [$C(CH_3)_2$], 105.0 (C-1), 84.2 (C-2), 82.9 (C-4), 80.0 (C-3), 50.6 (C-5), 26.6, 26.5 (CH_3). $[\alpha]_D^{20}$ +57 (*c* 1.0, CH_2Cl_2).

2.4. General procedures for preparing glucotriazoles 19a–j

A round-bottomed flask equipped with a magnetic stirring bar was loaded with **18** (1 mmol), the corresponding alkyne (0.9 mmol), $CuSO_4{\cdot}5H_2O$ (11.2 mg, 0.048 mmol), sodium ascorbate (26.5 mg, 0.13 mmol), CH_2Cl_2 (0.85 mL), and water (0.85 mL). The reaction proceeded for 12 h at room temperature, and then the reaction media was dissolved in CH_2Cl_2 (10 mL) and water (10 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure, and the crude product was purified by column chromatography on silica-gel and eluted with an increasing polarity gradient mixture of hexane and EtOAc to afford the corresponding 1,2,3-glucotriazole.[55]

2.4.1. 1,2-*O*-Isopropylidene-3-*C*-phenyl-5-(4-(1-hydroxycyclohexyl)-1*H*-1,2,3-triazole-1-yl)-α-D-ribofuranose (19a)

The reaction produced **19a** in a 90% yield as a white solid. Mp: 189–191 °C. IR ν_{max} (cm^{-1}; film): 1375 ([$C(CH_3)_2$]), 3493 (OH). ^{1}H NMR (300 MHz, $CDCl_3$) δ (*J* in Hz): 7.37–7.46 (m, 6H, phenyl and H-triazole), 4.50 (d, 1H, *J* = 3.9, H-2), 6.16 (d, 1H, *J* = 3.9, H-1), 4.42–4.35 (m, 2H, H-4, H-5a or H-5b), 3.59–3.67 (m, 1H, H-5a or H-5b), 3.52 (s, 1H, OH), 1.52–1.92 (m, 10H, cyclohexyl), 1.59 (s, 3H, H-7), 1.40 (s, 3H, H-8). ^{13}C NMR (75 MHz, $CDCl_3$) δ: 137.8 (C-1-phenyl; C-4-triazole); 128.6, 125.1 (C-2–C-6-phenyl), 128.3 (C-5-triazole), 113.2 [$C(CH_3)_2$], 105.0 (C-1), 84.2 (C-4), 82.4 (C-2), 80.3 (C-3), 69.3 (C-2-cyclohexyl), 50.2 (C-5), 38.1 (C-6-cyclohexyl), 37.9 (C-5-cyclohexyl), 26.5, 26.4 (CH_3), 25.3 (C-4-cyclohexyl), 21.9 (C-3-cyclohexyl). $[\alpha]_D^{20}$ +41 (*c* 1.1, CH_2Cl_2). MS *m/z* Calcd for $C_{22}H_{29}N_3O_5$: 415.2101. Found: 416.2168 ($M^{+\cdot}$+1). Anal. Calcd for $C_{22}H_{29}N_3O_5$: C, 63.60; H, 7.04; N, 10.11. Found: C, 63.79; H, 7.09; N, 10.31.

2.4.2. 1,2-*O*-Isopropylidene-3-*C*-phenyl-5-(4-(phenoxymethyl)-1*H*-1,2,3-triazole-1-yl)-α-D-ribofuranose (19b)

The reaction produced **19b** in a 90% yield as a white solid. Mp: 129–130 °C. IR ν_{max} (cm^{-1}; film): 1377 ([$C(CH_3)_2$]), 3476 (OH). ^{1}H NMR (300 MHz, $CDCl_3$) δ (*J* in Hz): 7.61 (1H, s, H-triazole), 7.35–7.45 (5H, m, phenyl), 6.93–7.30 (5H, m, phenoxy), 6.16 (1H, d, *J* = 4.1, H-1), 5.17 (2H, s, CH_2), 4.50 (1H, d, *J* = 3.9, H-2), 4.42 (1H, dd, *J* = 4.4 and 2.4, H-4), 4.35 (1H, dd, *J* = 9.3, 2.4, H-5a or H-5b), 3.65 (1H, dd, *J* = 14.4, 9.3, H-5a or H-5b), 3.38 (1H, s, OH), 1.60 (3H, s, CH_3), 1.40 (3H, s, CH_3). ^{13}C NMR (75 MHz, $CDCl_3$) δ: 158.2 (C-1-phenoxy), 144.2 (C-triazole), 137.7 (C-1 phenyl), 129.4 (C-5-triazole), 128.7, 128.3, 125.0, 123.6, 121.1, 114.7 (C-2–C-6-phenyl and phenoxy), 113.2 [$C(CH_3)_2$], 105.1 (C-1), 84.1 (C-4), 82.5 (C-2), 80.2 (C-3), 61.9 (CH_2), 50.2 (C-5), 26.5, 26.4 (CH_3). $[\alpha]_D^{20}$ +39 (*c* 1.1, CH_2Cl_2). MS *m/z* Calcd for $C_{23}H_{25}N_3O_5$: 423.1788. Found: 424.1871 ($M^{+\cdot}$+1). Anal. Calcd for $C_{23}H_{25}N_3O_5$: C, 65.24; H, 5.95; N, 9.92. Found: C, 65.42; H, 6.20; N, 9.98.

2.4.3. 1,2-*O*-Isopropylidene-3-*C*-phenyl-5-(4-(hydroxymethyl)-1*H*-1,2,3-triazole-1-yl)-α-D-ribofuranose (19c)

The reaction produced **19c** in an 86% yield as a yellow oil. IR ν_{max} (cm^{-1}; film): 1377 ([$C(CH_3)_2$]), 3476 (OH). ^{1}H NMR (300 MHz, $CDCl_3$) δ (*J* in Hz): 7.55 (1H, s, H-triazole), 7.35–7.47 (5H, m, phenyl), 6.15 (1H, d, *J* = 4.1, H-1), 4.74 (2H, s, CH_2), 4.50 (1H, d, *J* = 3.9, H-2), 4.42 (1H, dd, *J* = 14.4, 2.4, H-4), 4.34 (1H, dd, *J* = 9.5, 2.4, H-5a or H-5b), 3.65 (1H, dd, *J* = 14.4, 9.5, H-5a or H-5b), 1.58 (3H, s, CH_3), 1.40 (3H, s, CH_3). ^{13}C NMR (75 MHz, $CDCl_3$) δ: 147.7 (C-4-triazole), 137.7 (C-1-phenyl), 128.7, 128.3, 125.1, 122.6 (C-2–C-6-phenyl and C-5-triazole), 113.2 [$C(CH_3)_2$], 105.2 (C-1), 56.2 (CH_2), 50.2 (C-5), 84.1 (C-4), 82.4 (C-2), 80.3 (C-3), 26.4, 26.4 (CH_3). $[\alpha]_D^{20}$ +49 (*c* 1.0, CH_2Cl_2). MS *m/z* Calcd for $C_{17}H_{21}N_3O_5$: 347.1475. Found: 348.1522 ($M^{+\cdot}$+1).

2.4.4. 1,2-*O*-Isopropylidene-3-*C*-phenyl-5-((4-(tetrahydro-2*H*-pyran-2-yloxi)methyl)-1*H*-1,2,3-triazole-1-yl)-α-D-ribofuranose (19d)

The reaction produced **19d** in an 85% yield as a white solid. Mp: 136–138 °C. IR ν_{max} (cm^{-1}; film): 1372 ([$C(CH_3)_2$]), 3400 (OH). ^{1}H NMR (300 MHz, $CDCl_3$) δ: 7.56 (1H, d, *J* = 1.9, H-triazole), 7.35–7.45 (5H, m, phenyl), 6.16 (1H, d, *J* = 3.9, H-1), 4.83 (1H, dd, *J* = 12.4, 2.9, CH_2), 4.71–4.74 (1H, m, H-2-tetrahydropyran), 4.61 (1H, dd, *J* = 12.4, 5.6, CH_2), 4.50 (1H, d, *J* = 3.9, H-2), 4.42 (1H, dd, *J* = 14.4, 2.2, H-4), 4.34 (1H, dd, *J* = 9.3, 2.2, H-5a or H-5b), 3.84–3.92 (1H, m, H-6a or H-6b-tetrahydropyran), 3.63 (1H, dd, *J* = 9.3, 4.4, H-5a or H-5b), 3.51–3.59 (1H, m, H-6a or H-6b-tetrahydropyran), 3.40 (1H, s, OH), 1.60 (3H, s, CH_3), 1.49–1.57, 1.68–1.84 (6H, m, H-3-H-5-tetrahydropyran), 1.40 (3H, s, CH_3). ^{13}C NMR (75 MHz, $CDCl_3$) δ: 145.1 (C-4-triazole″), 137.7 (C-1-phenyl), 128.6, 128.3, 125.0 (C-2–C-6-phenyl), 123.4 (C-5-triazole), 113.2 [$C(CH_3)_2$], 105.0 (C-1), 98.0, 98.1 (C-2-tetrahydropyran), 84.1 (C-4), 82.5 (C-2), 80.2 (C-3), 62.0, 62.2 (CH_2), 60.4 (C-3-tetrahydropyran), 50.1 (C-5), 30.3, 30.4 (C-6-tetrahydropyran), 26.5 (CH_3), 26.4 (CH_3), 25.3 (C-4-tetrahydropyran), 19.1, 19.2 (C-5-tetrahydropyran). $[\alpha]_D^{20}$ +30 (*c* 1.1, CH_2Cl_2). MS *m/z* Calcd for $C_{22}H_{29}N_3O_6$: 431.2050. Found: 432.2229 ($M^{+\cdot}$+1). Anal. Calcd for $C_{22}H_{29}N_3O_6$: C, 61.24; H, 6.77; N, 9.74. Found: C, 61.39; H, 6.92; N, 10.08.

2.4.5. 1,2-*O*-Isopropylidene-3-*C*-phenyl-5-(4-(2-hydroxy-4-methylpentan-2-yl)-1*H*-1,2,3-triazole-1-yl)-α-D-ribofuranose (19e)

The reaction produced **19e** in a 90% yield as a white solid. Mp: 143–144 °C. IR ν_{max} (cm^{-1}; film): 1375 ([$C(CH_3)_2$]), 3465 (OH). ^{1}H NMR (300 MHz, $CDCl_3$) δ (*J* in Hz): 7.36–7.44 (6H, m, phenyl and H-triazole), 6.16 (1H, d, *J* = 3.9, H-1), 4.49 (1H, d, *J* = 3.9, H-2), 4.32–4.43 (2H, m, H-4, H-5a or H-5b), 3.60–3.68 (1H, m, H-5a or H-5b), 3.41 (1H, s, OH), 1.77 (2H, dd, *J* = 6.6, 5.9, CH_2), 1.59 (3H, s, CH_3), 1.57 (3H, d, *J* = 3.2, CH_3), 1.40 (3H, s, CH_3), 0.82 (3H, dd, *J* = 6.6, 1.2, CH_3), 0.81 (3H, dd, *J* = 6.6, 5.3, CH_3). ^{13}C NMR (75 MHz, $CDCl_3$) δ: 155.2 (C-4-triazole), 137.8 (C-1-phenyl), 128.6, 128.3, 125.1 (C-2–C-6-phenyl), 120.5 (C-5-triazole″), 113.1 [$C(CH_3)_2$], 105.0 (C-1), 84.1 (C-4), 82.5 (C-2), 80.3 (C-3), 71.3, 71.1 ($COHCH_3$), 51.6, 51.5 (CH_2), 50.1 (C-5), 29.2, 28.8 (CH_3), 26.5, 26.4

(CH_3), 24.4 (CH_3), 24.2 (C-CH_3). $[\alpha]_D^{20}$ +48 (*c* 1.0, CH_2Cl_2). MS *m/z* Calcd for $C_{22}H_{31}N_3O_5$: 417.2258. Found: 418.2310 (for $M^{+\cdot}$+1). Anal. Calcd for $C_{22}H_{31}N_3O_5$: C, 63.29; H, 7.48; N, 10.06. Found: C, 63.46; H, 7.55; N, 10.12.

2.4.6. 1,2-*O*-Isopropylidene-3-*C*-phenyl-5-(4-cyclohexenyl-1*H*-1,2,3-triaze-1-yl)-α-D-ribofuranose (19f)

The reaction produced **19f** in an 89% yield as a white solid. Mp: 185–187 °C. IR ν_{max} (cm^{-1}; film): 1375 ([$C(CH_3)_2$]), 3493 (OH). ^1H NMR (300 MHz, $CDCl_3$) δ (*J* in Hz): 7.36–7.46 (6H, m, phenyl and triazole), 6.45–6.49 (1H, m, H-2-cyclohexenyl), 6.16 (1H, d, *J* = 4.1, H-1), 4.50 (1H, d, *J* = 3.9, H-2), 4.42 (1H, dd, *J* = 14.6, 2.4, H-4), 4.32 (1H, dd, *J* = 9.5, 2.4, H-5a or H-5b), 3.59 (1H, dd, *J* = 14.6, 9.5, H-5a or H-5b), 3.46 (1H, s, OH), 2.20–2.15 (4H, m, H-4 and H-6-cyclohexenyl), 1.76–1.63 (4H, m, H-3 and H-5-cyclohexenyl), 1.58 (3H, s, CH_3), 1.40 (3H, s, CH_3). ^{13}C NMR (75 MHz, $CDCl_3$) δ: 149.4 (C-1-cyclohexenyl), 137.8 (C-4-triazole), 127.2 (C-1-phenyl), 128.6, 128.2, 127.2, 124.8 (C-2–C-6-phenyl), 125.1 (C-2-cyclohexenyl), 119.3 (C-5-cyclohexenyl), 113.2 [*C*(CH_3)$_2$], 105.1 (C-1), 84.1 (C-4), 82.5 (C-2), 80.3 (C-3), 50.1 (C-5), 26.5, 26.4 (CH_3), 26.2, 25.2, 22.4, 22.2 (C-3–C-6-cyclohexenyl). $[\alpha]_D^{20}$ +39 (*c* 1.1, CH_2Cl_2). MS *m/z* Calcd for $C_{22}H_{27}N_3O_4$: 397.1996. Found: 398.2059 ($M^{+\cdot}$+1). Anal. Calcd for $C_{22}H_{27}N_3O_4$: C, 66.48; H, 6.85; N, 10.57. Found: C, 66.71; H, 6.97; N, 10.61.

2.4.7. 1,2-*O*-Isopropylidene-3-*C*-phenyl-5-(4-(3-chloropropyl)-1*H*-1,2,3-triazole-1-yl)-α-D-ribofuranose (19g)

The reaction produced **19g** in a 92% yield as a white solid. Mp: 108–109 °C. IR ν_{max} (cm^{-1}; film): 1376 [$C(CH_3)_2$], 3449 (OH). ^1H NMR (300 MHz, $CDCl_3$) δ (*J* in Hz): 7.79–7.82 (2H, m, H-3 and H-5-phenyl), 7.31–7.50 (3H, m, H-2, H-4 and H-6-phenyl), 7.33 (1H, s, triazole), 6.16 (1H, d, *J* = 3.9, H-1), 4.50 (1H, d, *J* = 3.9, H-2), 4.39 (1H, dd, *J* = 14.4, 2.4, H-5a or H-5b), 4.33 (1H, dd, *J* = 9.0, 2.4, H-4), 3.62 (1H, dd, *J* = 14.4, 9.0, H-5a ou H-5b), 3.53–3.60 (2H, m, CH_2), 3.42 (1H, s, OH), 2.85 (2H, t, *J* = 7.3, CH_2), 2.08–2.18 (2H, m, CH_2), 1.60 (3H, s, CH_3), 1.40 (3H, s, CH_3). ^{13}C NMR (75 MHz, $CDCl_3$) δ: 146.3 (C-4-triazole), 137.8 (C-1-phenyl), 128.6, 128.2, 125.0 (C-2–C-6-phenyl), 122.0 (C-5-triazole), 113.1 [*C*(CH_3)$_2$], 105.0 (C-1), 84.1 (C-4), 82.5 (C-2), 80.2 (C-3), 50.5 (C-5), 44.1 (CH_2), 31.7 (CH_2), 26.5, 26.4 (CH_3), 22.6 (CH_2). $[\alpha]_D^{20}$ +39 (*c* 1.1, CH_2Cl_2). MS *m/z* Calcd for $C_{19}H_{24}ClN_3O_4$: 393.1449. Found: 394.1455 ($M^{+\cdot}$+1). Anal. Calcd for $C_{19}H_{24}ClN_3O_4$: C, 57.94; H, 6.14; N, 10.67. Found: C, 58.08; H, 6.24; N, 10.80.

2.4.8. 1,2-*O*-Isopropylidene-3-*C*-phenyl-5-(4-(2-hydroxypropan-2-yl)-1*H*-1,2,3-triazole-1-yl)-α-D-ribofuranose (19h)

The reaction produced **19h** in an 86% yield as a white solid. Mp: 120–122 °C. IR ν_{max} (cm^{-1}; film): 1385 [$C(CH_3)_2$], 3369 (OH). ^1H NMR (300 MHz, $CDCl_3$) δ (*J* in Hz): 7.39–7.44 (6H, m, phenyl and triazole), 6.16 (1H, d, *J* = 3.9, H-1), 4.50 (1H, d, *J* = 3.9, H-2), 4.35-4.43 (2H, m, H-4, H-5a or H-5b), 3.58–3.66 (1H, m, H-5a or H-5b), 3.52 (1H, s, OH), 1.61 (3H, s, CH_3), 1.60 (3H, s, CH_3), 1.60 (3H, s, CH_3), 1.40 (3H, s, CH_3). ^{13}C NMR (75 MHz, $CDCl_3$) δ: 155.4 (C-4-triazole), 137.8 (C-1-phenyl), 128.6, 128.3, 125.1 (C-2–C-6-phenyl), 113.1 [*C*(CH_3)$_2$], 105.0 (C-1), 85.7 (C-5-triazole), 84.1 (C-4), 82.4 (C-2), 80.3 (C-3), 68.2 (*C*(CH_3)$_2$OH), 50.2 (C-5), 30.3 (C-H_3), 30.2 (CH_3), 26.5, 26.4 (CH_3). $[\alpha]_D^{20}$ +50 (*c* 1.0, CH_2Cl_2). MS *m/z* Calcd for $C_{19}H_{25}N_3O_5$: 375.1788. Found: 376.1867 ($M^{+\cdot}$+1). Anal. Calcd for $C_{19}H_{25}N_3O_5$: C, 60.79; H, 6.71; N, 11.19. Found: C, 60.89; H, 6.81; N, 11.22.

2.4.9. 1,2-*O*-Isopropylidene-3-*C*-phenyl-5-(4-phenyl-1*H*-1,2,3-triazole-1-yl)-α-D-ribofuranose (19i)

The reaction produced **19i** in a 90% yield as a white solid. Mp: 192–193 °C. IR ν_{max} (cm^{-1}; film): 1374 [$C(CH_3)_2$], 3484 (OH). ^1H NMR (300 MHz, $CDCl_3$) δ (*J* in Hz): 7.79–7.82 (2H, m, phenyl), 7.78 (1H, s, triazole), 7.31–7.50 (8H, m, phenyl), 6.19 (1H, d, *J* = 3.9, H-1), 4.52 (1H, d, *J* = 3.6, H-2), 4.50 (1H, dd, *J* = 13.7, 2.2, H-5a or H-5b), 4.39 (1H, dd, *J* = 9.3, 2.2, H-4), 3.68 (1H, dd, *J* = 14.6, 9.5, H-5a or H-5b), 3.5 (1H, s, OH), 1.58 (3H, s, CH_3), 1.40 (3H, s, CH_3). ^{13}C NMR (75 MHz, $CDCl_3$) δ: 147.7 (C-1′-phenyl), 137.8 (C-1-phenyl), 130.5 (C-4′-phenyl), 128.7, 128.3, 128.0, 125.7, 125.1 (C-2–C-6-phenyl and C-2′–C-6′-phenyl), 120.6 (C-5-triazole), 113.2 [*C*(CH_3)$_2$], 105.1 (C-1), 84.2 (C-4), 82.4 (C-2), 80.3 (C-3), 50.3 (C-5), 26.5, 26.4 (CH_3). $[\alpha]_D^{20}$ +52 (*c* 1.0, CH_2Cl_2). MS *m/z* Calcd for $C_{22}H_{23}N_3O_4$: 393.1683. Found: 394.1790 ($M^{+\cdot}$+1). Anal. Calcd for $C_{22}H_{23}N_3O_4$: C, 67.16; H, 5.89; N, 10.68. Found: C, 60.31; H, 5.97; N, 10.82.

2.4.10. 1,2-*O*-Isopropylidene-3-*C*-phenyl-5-(4-(3-aminophenyl)-1*H*-1,2,3-triazole-1-yl)-α-D-ribofuranose (19j)

The reaction produced **19j** in a 93% yield as a yellow solid. Mp: 85–87 °C. IR ν_{max} (cm^{-1}; film): 1376 [$C(CH_3)_2$], 3367 (OH). ^1H NMR (300 MHz, $CDCl_3$) δ (*J* in Hz): 7.73 (1H, s, triazole), 7.38–7.46 (5H, m, phenyl), 7.10–7.20 (4H, m, aniline), 6.19 (1H, d, *J* = 3.8, H-1), 4.51 (1H, d, *J* = 3.8, H-2), 4.47 (1H, dd, *J* = 14.5, 2.2, H-5a or H-5b), 4.37 (1H, dd, *J* = 9.4, 2.2, H-4), 3.64 (1H, dd, *J* = 14.5, 9.4, H-5a or H-5a), 1.59 (3H, s, CH_3), 1.40 (3H, s, CH_3). ^{13}C NMR (75 MHz, $CDCl_3$) δ: 147.8 (C-3-aniline), 146.7 (C-4-aniline), 137.8 (C-1-phenyl), 131.4 (C-1-aniline), 129.6, 128.7, 128.3, 125.1 (C-2–C-6-phenyl), 120.6 (C-5-triazole), 116.0, 114.8, 112.2 (C-2, C-4–C-6-aniline), 113.2 [*C*(CH_3)$_2$], 82.5 (C-2), 105.0 (C-1), 84.1 (C-4), 80.3 (C-3), 50.2 (C-5), 26.5, 26.4 (CH_3). $[\alpha]_D^{20}$ +37 (*c* 1.1, CH_2Cl_2). MS *m/z* Calcd for $C_{22}H_{24}N_4O_4$: 408.1792. Found: 409.1816 ($M^{+\cdot}$+1). Anal. Calcd for $C_{22}H_{24}N_4O_4$: C, 64.69; H, 5.92; N, 13.72. Found: C, 64.82; H, 6.01; N, 13.90.

2.5. α-Glucosidase inhibition

All compounds were initially screened for α-glucosidase inhibition as described by Matsui and co-workers.[56] The enzyme α-glucosidase from *Saccharomyces cerevisiae* used was obtained from Sigma Aldrich Chemical Co., USA (EC. 3.2.1.20, Cat. No. G0660). The activity of α-glucosidase was determined by monitoring the release of *p*-nitrophenol from *p*-nitrophenyl α-D-glucopyranoside at 405 nm. The compounds were initially evaluated for their ability to inhibit in a fixed concentration of 580 mM, and the results are expressed in percentage inhibition against the test performed in the absence of the inhibitor. The active compounds were then characterized with respect to the concentration required to inhibit 50% of the activity of α-glucosidase under the test conditions. In these tests, acarbose was used as standard for comparison. Most of the compounds were found to be inactive against yeast maltase except for glycotriazoles **19i** and **19f**. Next, the determination of the IC_{50} for these compounds revealed that **19i** (119.5 ± 0.1 μM) had a similar potency to acarbose (IC_{50} 108.8 ± 12 μM), but **19f** (247.4 ± 34 μM) was twofold less active.

3. Discussion

Our results showed that glycotriazoles **19f** and **19i** were the most potent in the inhibition assay on the α-glucosidase enzyme. However, their IC_{50} values were higher than those of acarbose, which was used in our test as the standard drug. The other compounds prepared in this series showed no significant inhibitory activity. The comparison of these new compounds with previously synthesized 1,2,3-triazoles **8** and **9** (Fig. 2)[48] revealed that the introduction of the phenyl group at the C-3 position did not produce the desired effect of increasing the inhibitory activity. Although no molecular modeling or docking studies have been conducted of these substances, we expected that the more rigid li-

gands would be less affected by entropic issues at the active site of the enzyme than the more flexible ones; therefore, they should have a more favorable energy profile. However, the results in this series did not follow this trend, which leads us to believe that the volume of the phenyl ring offset the negatively entropic gain in question.

The results obtained so far showed that the carbohydrate unit present in the compounds in this series plays an important role in the inhibitory activity against the enzyme because the introduction of the phenyl group at the C-3 position of the carbohydrate significantly altered the interaction with the enzyme.

4. Conclusion

We developed a synthetic route in nine steps to synthesize new 1,2,3-triazole glycoconjugates (**19a–j**) from D-glucose (**1**) in 14% overall yield. These 1,2,3-triazoles were evaluated in in vitro assays and for their ability to inhibit the enzyme α-glucosidase. Most of them had low activity or were inactive when compared with acarbose. However, compound **19i** had an activity that was comparable with that of standard drugs.

References

1. Dwek, R. A. *Chem. Rev.* **1996**, *96*, 683–720.
2. Kim, J. Y.; Lee, J. W.; Kim, Y. S.; Ryu, Y. B.; Kim, S.; Ryu, H. W.; Curtis-Long, M. J.; Lee, K. W.; Lee, W. S.; Park, K. H. *Chembiochem* **2010**, *11*, 2125–2131.
3. Courageot, M.-P.; Frenkiel, M.-P.; dos Santos, C. D.; Deubel, V.; Desprès, P. *J. Virol.* **2000**, *74*, 564–572.
4. van den Broek, L. A. G. M. Azasugars: Chemistry and their Biological Activity as Potential Anti-HIV Drugs. In *Carbohydrates in Drug Design*; Witczak, Z. J., Nieforth, K. A., Eds.; Marcel Dekker: New York, 1997; p 471.
5. Gross, P. E.; Baker, M. A.; Carver, J. P.; Dennis, J. W. *Clin. Cancer Res.* **1995**, *1*, 935–944.
6. Bernacki, R. J.; Niedbala, M. J.; Korytnyk, W. *Cancer Metastasis Rev.* **1985**, *4*, 81–101.
7. Watson, A. A.; Fleet, G. W. J.; Asano, N.; Molyneux, R. J.; Nash, R. J. *Phytochemistry* **2001**, *56*, 265–295.
8. Tattersall, R. *Diabetes Med.* **1993**, *10*, 688–693.
9. Asano, N. *Glycobiology* **2003**, *13*, 93–104.
10. Schmidt, D. D.; Frommer, W.; Müller, L.; Junge, B.; Wingender, W.; Truscheit, E. *Naturwissenshaften* **1977**, *64*, 535–536.
11. Hanozet, G.; Pircher, H. P.; Vanni, P.; Oesch, B.; Semenza, G. *J. Biol. Chem.* **1981**, *256*, 3703–3711.
12. Chiasson, J.-L.; Josse, R. G.; Hunt, J. A.; Palmason, C.; Rodger, N. W.; Ross, S. A.; Ryan, E. A.; Tan, M. H.; Wolever, T. M. S. *Ann. Intern. Med.* **1994**, *121*, 928–935.
13. Holman, R. R.; Cull, C. A.; Turner, R. C. *Diabetes Care* **1999**, *22*, 960–964.
14. Jenkins, D. J.; Taylor, R. H.; Goff, D. V.; Fielden, H.; Misiewicz, J. J.; Sarson, D. L.; Bloom, S. R.; Alberti, K. G. *Diabetes* **1981**, *30*, 951–954.
15. Taylor, R. H.; Jenkins, D. J.; Barker, H. M.; Fielden, H.; Goff, D. V.; Misiewicz, J. J.; Lee, D. A.; Allen, H. B.; MacDonald, G.; Wallrabe, H. *Diabetes Care* **1982**, *5*, 92–96.
16. Brogard, J. M.; Willemin, B.; Blicklé, J. F.; Lamalle, A. M.; Stahl, A. *Rev. Med. Interne* **1989**, *10*, 365–374.
17. Tschamber, T.; Gessier, F.; Dubost, E.; Newsome, J.; Tarnus, C.; Kohler, J.; Neuburger, M.; Streith, J. *Bioorg. Med. Chem.* **2003**, *11*, 3559–3568.
18. Granier, T.; Panday, N.; Vasella, A. *Helv. Chim. Acta* **1997**, *80*, 979–987.
19. Krulle, T. M.; de la Fuente, C.; Pickering, L.; Aplin, R. T.; Tsisanou, K. E.; Zographos, S. E.; Oinkomakos, N. G.; Nash, R. J.; Griffiths, R. C.; Fleet, G. W. J. *Tetrahedron: Asymmetry* **1997**, *8*, 3807–3820.
20. Périon, R.; Ferriéres, V.; García-Moreno, M. I.; Mellet, C. O.; Duval, R.; Fernández, J. M. G.; Plusquellec, D. *Tetrahedron* **2005**, *61*, 9118–9128.
21. Rossi, L. L.; Basu, A. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 3596–3599.
22. Tatsuta, K.; Ikeda, Y.; Miura, S. *J. Antibiot.* **1996**, *49*, 836–839.
23. Castro, S.; Cherney, E. C.; Snyder, N. L.; Peczuh, M. W. *Carbohydr. Res.* **2007**, *342*, 1366–1372.
24. Sabesan, S. US patent 2005124563–A1.
25. Davis, B. G.; Brandstetter, T. W.; Hackett, L.; Winchester, B. G.; Nash, R. J.; Watson, A. A.; Griffiths, R. C.; Smith, C.; Fleet, G. W. J. *Tetrahedron* **1999**, *55*, 4489–4500.
26. Davis, B. G.; Nash, R. J.; Watson, A. A.; Smith, C.; Fleet, G. W. J. *Tetrahedron* **1999**, *55*, 4501–4520.
27. Kolb, H. C.; Finn, M. G.; Sharpless, K. B. *Angew. Chem., Int. Ed.* **2001**, *40*, 2004–2021.
28. For recent reviews see: (a) Kolb, H. C.; Sharpless, K. B. *Drug Discovery Today* **2003**, *8*, 1128–1137; (b) Wang, Q.; Chittaboina, S.; Barnhill, H. N. *Lett. Org. Chem.* **2005**, *2*, 293–301; (c) Bock, V. D.; Perciaccante, R.; Jansen, T. P.; Hiemstra, H.; Maarseveen, J. H. *Org. Lett.* **2006**, *8*, 919–922.
29. Kacprzak, K. *Synlett* **2005**, 943–946.
30. Costa, M. S.; Boechat, N.; Rangel, E. A.; da Silva, F. C.; de Souza, A. M. T.; Rodrigues, C. R.; Castro, H. C.; Junior, N. I.; Lourenço, M. C. S.; Wardell, S. M. S. V.; Ferreira, V. F. *Bioorg. Med. Chem.* **2006**, *14*, 8644–8653.
31. Cunha, A. C.; Figueiredo, J. M.; Tributino, J.; Miranda, A. L.; Castro, H. C.; Zingali, R. B.; Fraga, C. A.; de Souza, M. C. B. V.; Ferreira, V. F.; Barreiro, E. J. *Bioorg. Med. Chem.* **2003**, *11*, 2051–2059.
32. Menegatti, R.; Cunha, A. C.; Ferreira, V. F.; Perreira, E. F. R.; El-Nabawi, A.; Eldefrawi, A.; Albuquerque, T. E. X.; Neves, G.; Rates, S. M. K.; Fraga, C. A. M.; Barreiro, E. J. *Bioorg. Med. Chem.* **2003**, *11*, 4807–4813.
33. Kelley, J. L.; Koble, C. S.; Davis, R. G.; McLean, E. W.; Soroko, F. E.; Cooper, B. R. *J. Med. Chem.* **1995**, *38*, 4131–4134.
34. Biagi, G.; Dell'Omodarme, G.; Ferretti, M.; Giorgi, I.; Livi, O.; Scartoni, V. *Farmaco* **1990**, *45*, 1181–1192.
35. Biagi, G.; Livi, O.; Scartoni, V.; Lucacchini, A.; Mazzoni, M. R. *Farmaco* **1986**, *41*, 597–610.
36. Biagi, G.; Dell'Omodarme, G.; Ferretti, M.; Giorgi, I.; Livi, O.; Scartoni, V. *Farmaco* **1992**, *47*, 335–344.
37. Biagi, G.; Ferretti, M.; Giorgi, I.; Livi, O.; Scartoni, V.; Lucacchini, A. *Farmaco* **1993**, *48*, 1159–1165.
38. Buckle, D. R.; Rockell, C. J.; Smith, H.; Spicer, B. A. *J. Med. Chem.* **1984**, *27*, 223–227.
39. Buckle, D. R.; Rockell, C.; Smith, H.; Spicer, B. A. *J. Med. Chem.* **1986**, *29*, 2262–2267.
40. San-Felix, A.; Velazquez, S.; Perez-Perez, M. J.; Balzarini, J.; De Clercq, E.; Camarasa, M. J. *J. Med. Chem.* **1994**, *37*, 453–460.
41. Velazquez, S.; Alvarez, R.; Perez, C.; Gago, F.; De Clercq, E.; Balzarini, J.; Camarasa, M. J. *Antiviral Chem. Chemother.* **1998**, *9*, 481–489.
42. Al-Masoudi, N. A.; Al-Soud, Y. A.; Abdul-Zahra, A. *Heteroatom Chem.* **2004**, *15*, 380–387.
43. da Silva, F. C.; de Souza, M. C. B. V.; Frugulhetti, I. C. P. P.; Castro, H. C.; Souza, S. L. O.; de Souza, T. M. L.; Rodrigues, D. Q.; Souza, A. M. T.; Abreu, P. A.; Passamani, F.; Rodrigues, C. R.; Ferreira, V. F. *Eur. J. Med. Chem.* **2009**, *44*, 373–383.
44. Holla, B. S.; Mahalinga, M.; Karthikeyan, M. S.; Poojary, B.; Akberali, P. M.; Kumari, N. S. *Eur. J. Med. Chem.* **2005**, *40*, 1173–1178.
45. Dabak, K.; Sezer, O.; Akar, A.; Anac, O. *Eur. J. Med. Chem.* **2003**, *38*, 215–218.
46. Mares, D.; Romagnoli, C.; Andreotti, E.; Manfrini, M.; Vicentini, C. B. *J. Agric. Food Chem.* **2004**, *52*, 2003–2009.
47. Willner, D.; Jelenevsky, A. M.; Cheney, L. C. *J. Med. Chem.* **1972**, *15*, 948–951.
48. Ferreira, S. B.; Sodero, A. C.; Cardoso, M. F.; Lima, E. S.; Kaiser, C. R.; Silva, F. P.; Ferreira, V. F. *J. Med. Chem.* **2010**, *53*, 2364–2375.
49. Ferreira, V. F. *Quim. Nova* **1992**, *15*, 348–350.
50. Zhang, M.; Cui, Y.; Liu, X.; Li, J.; Ma, L.; Zhang, L. *Bopuxue Zazhi* **1999**, *16*, 219–224.
51. Brigtte, V. G. J.; Caris, M. G.; Zwanenbury, B.; Chittenden, J. F. *Recl. Trav. Chim. Pays-Bas* **1992**, *111*, 348–352.
52. da Rocha, D. R.; Ferreira, V. F.; Garcez-do-Carmo, L.; Santos, W. C. *Lett. Drug Des. Disc.* **2008**, *5*, 236–242.
53. Winans, K. A.; Bertozzi, C. R. *Chem. Biol.* **2002**, *9*, 113–129.
54. Hill, S.; Hough, L.; Richardson, A. C. *Carbohydr. Res.* **1968**, *8*, 17–18.
55. Lee, B. Y.; Park, S. R.; Jeon, H. B.; Kim, K. S. *Tetrahedron Lett.* **2006**, *47*, 5105–5109.
56. Matsui, T.; Yoshimoto, C.; Osajima, K.; Oki, T.; Osajima, Y. *Biosci., Biotechnol., Biochem.* **1996**, *60*, 2019–2022.